Weight loss is real and painful, right? Science shows that once people have gained a lot of weight, it’s difficult for them to lose it with only diet control. After the Eli Lilly weight loss drug in India gained popularity, it felt like obesity in India is an officially declared disease that needs treatment. However, one important factor many people are concerned about is the Eli Lilly weight loss drug price in India, which has sparked discussions about accessibility and affordability for those in need of a solution.
You know, dealing with obesity isn’t just about putting on those extra pounds. It can actually open the door to a whole mess of other health issues, like heart problems, type 2 diabetes, certain cancers, breathing problems, joint problems, and mental health issues like depression and anxiety.
The data related to metabolic diseases in India is quite surprising. Over 50% of India suffer from metabolic diseases. Type-2 diabetes, fatty liver, and it’s hard to find a person who isn’t struggling with weight-loss techniques. Lilly’s weight loss drug, Mounjaro, is finally hitting the shelves in India. This is a game changer for obesity treatment. The arrival of this drug will be a huge shift in obesity treatment.
Obesity: How It Affects Your Health and What You Can Do About It
Let’s begin with the basics: obesity is a condition where the body accumulates too much fat, and unfortunately, it can worsen your overall quality of life. Obesity doesn’t just take a toll on your body; it can mess with your mental peace, too. Let’s explore how these high cholesterol levels in your body due to obesity, impact your overall health:
- High blood pressure and cholesterol levels can really put your heart at risk; heart diseases due to obesity can risk your life quality.
- Your joints experience extra strain due to heavy muscle gain, leading to pain and arthritis.
- The regulation of blood sugar levels in your body weakens due to high cholesterol levels, leading to a higher chance of developing type 2 diabetes.
- Breathing difficulties are more common in obese people, increasing the risk of sleep apnoea.
Read Also: Symptoms of IBS and Its Causes: Do I have IBS?
Top 3 Reasons the Fitness Industry Is Failing in India
A bad lifestyle alone isn’t to blame. The fitness industry in India is struggling for many reasons. Poor urban planning leaves little room for safe walking or outdoor exercise. Public parks are scarce, and footpaths are either non-existent or occupied. Staying active feels like a privilege, not a normal part of life.
- Stress levels are through the roof, and poor nutrition follows. Long working hours, exhausting commutes, and fast food create a cycle of unhealthy habits. Cooking nutritious meals takes effort, but ready-to-eat options are everywhere. For many, convenience wins over health.
- Decades ago, lifestyle diseases were rare. Now, diabetes and heart conditions are common across all age groups. Modern medicine makes chronic illnesses manageable, reducing the urgency to stay fit. If medication keeps things under control, why change habits? That mindset is dangerous but widespread.
- Diets play a massive role. Traditional meals are carb-heavy and protein-deficient, especially in rural areas. Refined grains, deep-fried snacks, and sugary drinks dominate Indian diets. The rise of packaged food only makes things worse. Poor dietary habits start young and last for life.
Also, exercise culture isn’t accessible to everyone. Gym memberships cost a fortune, and fitness trends cater to the upper class. Home workouts sound great, but without proper guidance, motivation fades. Walking should be the simplest form of exercise, yet cities make it difficult.
The rise of weight-loss drugs isn’t surprising. They promise quick results in a world where time is scarce. But do they fix the problem? Not really.
Fixing India’s fitness crisis requires more than individual effort. Cities need better planning, food choices must improve, and fitness must feel achievable. Without these changes, the cycle of poor health will continue.
Eli Lilly Weight Loss Drug in India: What is it?
Last week, Eli Lilly decided to roll out Mounjaro in India! Now, here’s something to wrap your mind around: India has more diabetics. And, if it keeps going the way it is trending now, over 30% of obese and diabetic sufferers in India will benefit.
Clinical trials and results
India’s escalating obesity and diabetes rates have intensified the search for effective treatments. Eli Lilly’s tirzepatide, marketed as Mounjaro, has shown promise in this area, particularly through its SURMOUNT clinical trials.
SURMOUNT Clinical Trials Overview
-
SURMOUNT-1: This trial evaluated tirzepatide in adults without type 2 diabetes who were obese or overweight with weight-related comorbidities. Participants achieved significant weight loss, with results indicating a reduced risk of progressing to diabetes by 94%.
-
SURMOUNT-2: Focused on individuals with type 2 diabetes, this study demonstrated that tirzepatide led to superior weight reduction versus placebo.
-
SURMOUNT-3: This trial assessed tirzepatide in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes.
-
SURMOUNT-4: Investigated the maintenance of weight loss with continued tirzepatide treatment. Participants who continued the medication experienced additional weight loss, while those who discontinued regained weight, highlighting the importance of ongoing therapy.
- SURMOUNT-5: Patients under the trial shed an average of 20.2% of their body weight over 72 weeks, which equals about 50.3 lbs (22.8 kg)! That’s pretty impressive, right? For a little comparison, the well-known drug Wegovy led to an average body weight decrease of just 13.7%, or roughly 33.1 lbs (15 kg).
The SURMOUNT trials underscore tirzepatide’s potential in addressing obesity and diabetes, conditions prevalent in India. By promoting substantial weight loss and improving metabolic health, tirzepatide could become a valuable component of comprehensive treatment strategies for Indian patients.
Consultation is Essential
While tirzepatide offers promising benefits, individual responses may vary. It’s crucial to consult a healthcare professional to determine its suitability based on personal health profiles and to receive tailored guidance.
In summary, the SURMOUNT trials highlight tirzepatide’s efficacy in weight management and diabetes care, offering a potential therapeutic option for individuals in India grappling with these health challenges.
Also Read: Top Fitness and Nutrition Trends in 2025
How will Lilly’s Weight Loss Drug Benefit Indians?
India’s escalating rates of obesity and diabetes have positioned it as the “diabetic capital of the world.” In response, Eli Lilly has introduced Mounjaro (tirzepatide) to the Indian market, aiming to address these pressing health concerns.
Understanding GLP-1 Agonists and Mounjaro’s Mechanism
Mounjaro belongs to a class of medications known as GLP-1 receptor agonists. These drugs mimic the glucagon-like peptide-1 (GLP-1) hormone, which plays a crucial role in regulating blood sugar levels and appetite. By activating GLP-1 receptors, these agonists enhance insulin secretion in response to high blood sugar, slow gastric emptying, and promote a feeling of fullness, thereby reducing food intake.
Potential Benefits for Indians
-
Blood Sugar Control: For individuals with type 2 diabetes, Mounjaro can improve blood sugar management by stimulating insulin release when glucose levels are elevated.
-
Weight Management: By inducing satiety and decreasing appetite, Mounjaro aids in weight loss, which is beneficial for both diabetic and non-diabetic individuals struggling with obesity.
Important Considerations
While Mounjaro offers promising benefits, it’s essential to approach its use with caution:
-
Side Effects: Potential adverse effects include nausea, vomiting, diarrhoea, and in rare cases, more severe conditions like pancreatitis.
-
Individual Responses: Efficacy and side effects can vary based on individual factors such as genetics, existing health conditions, and concurrent medications.
-
Lifestyle Integration: Mounjaro should complement, not replace, a healthy lifestyle. Optimal results are achieved when combined with a balanced diet and regular physical activity.
Attention: This drug can be used as a tool to help you lose weight and manage blood sugar. It works best when combined with a healthy lifestyle. Benefits are real, but the body types are different, and so are the reactions to the dose. Consult your doctor before taking this drug directly.
Eli Lilly Weight Loss Drug Price in India: Will it bother Indians
Eli Lilly’s weight loss drug price in India may surprise you. It may affect the pocket of Indians, but taking care of health really comes at a cost. The injection is priced at ₹4,375 for a 5 mg vial and ₹3,500 for a 2.5 mg vial, its lowest doses. But remember, the dosage of this weight loss drug depends on the significant weight loss. And the cost can go up to ₹28,000 for 5 kg weight loss in 8 weeks. Understand how will the price of this drug will vary once the patent expires:
With GLP-1 patent expiring in 2026, will weight loss drugs come to affordable range, or this will only for diabetes patients
byu/Various_Solid_4420 inindianmedschool
Read Also: Health and Wellness Importance in 2025: Am I healthy?
Wrapping Up
Indians may not have to struggle with obesity much longer, thanks to Eli Lilly’s weight-loss drug, Mounjaro (tirzepatide). Clinical trials have shown remarkable results, making it a potential breakthrough in obesity management. Lilly is now considering manufacturing the drug locally, which could bring the treatment closer to millions of Indian patients.
If production begins in India, it could reduce costs, making the drug more affordable and accessible. Many Indians suffer due to expensive medications and limited treatment options. A locally manufactured version of Mounjaro would help bridge this gap.
With pharmaceutical advancements and local production possibilities, obesity treatment in India may soon become more accessible. If Eli Lilly moves forward with its plans, this could be a major step toward tackling obesity and improving public health in the country.
FAQs
Q-1: What is the new drug from Eli Lilly for weight loss?
Eli Lilly Co. is gearing up to cure diabetes and obesity with its GLP-1 drug. The active ingredient in Mounjaro (tirzepatide) is being investigated as effective in weight loss. So, Eli Lilly’s new drug will effectively help people with obesity to lose weight
Q-2: How to get Eli Lilly weight loss drugs?
You can get prescribed Eli Lilly weight-loss medications by meeting with a healthcare provider. It is advisable to take weight-loss medicines after consulting the doctor, as it has some serious side effects.
Q-3: What are the most popular Eli Lilly drugs?
Some crowd-favourite medications from Eli Lilly. So, have you heard of Mounjaro and Trulicity? These diabetes medications aren’t just good for your health—they’re also raking in the bucks!
Q-4: How much does Eli Lilly’s weight loss drug cost?
The FDA has approved Mounjaro for weight loss. Eli Lilly has decided to sell it at the starting dose of 2.5 mg. Monthly treatment costs vary based on dosage; for instance, a 5 mg weekly dose totals approximately ₹16,000 per month.
Q-5: Who cannot take tirzepatide?
Tirzepatide (Mounjaro/Zepbound) should not be taken by individuals who are allergic to tirzepatide or any of its ingredients, those with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2, or individuals with severe gastrointestinal issues like gastroparesis. Always consult a healthcare provider before use.
About The Author
